<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="pmc">brjcancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">2900647</article-id><article-id pub-id-type="pmc">2246455</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. 'Nolvadex' Adjuvant Trial Organisation.</article-title></title-group><pub-date pub-type="ppub"><month>6</month><year>1988</year></pub-date><volume>57</volume><issue>6</issue><fpage>608</fpage><lpage>611</lpage><abstract><p>At a maximum follow up of 8 years (median 5 years 6 months) in a randomised trial of adjuvant tamoxifen versus no treatment as therapy for early breast cancer, a significant advantage persists for patients receiving 20 mg of tamoxifen daily for 2 years. This advantage is independent of menopausal status, stage, grade and ER status. Log hazard rate analysis fails to demonstrate a rebound effect on stopping the drug and suggests that more prolonged treatment might further improve results.</p></abstract></article-meta></front><body><supplementary-material content-type="scanned-pages"><graphic xlink:href="brjcancer00140-0084.tif" xlink:title="scanned-page" xlink:role="608" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00140-0085.tif" xlink:title="scanned-page" xlink:role="609" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00140-0086.tif" xlink:title="scanned-page" xlink:role="610" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00140-0087.tif" xlink:title="scanned-page" xlink:role="611" mimetype="image" mime-subtype="tiff"/></supplementary-material></body></article>

